• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • NMPA Guidelines to Successfully Register Coronavirus Protection Supplies for Sale in China

NMPA Guidelines to Successfully Register Coronavirus Protection Supplies for Sale in China

Tuesday, 12 May 2020 / Published in Medical Device

NMPA Guidelines to Successfully Register Coronavirus Protection Supplies for Sale in China

On 30.03.2020, the NMPA (National Medical Products Administration) released an overview of the latest regulatory standards in response to the coronavirus epidemic, guiding manufacturers, NMPA Legal Agents, and companies with the suitable pathway for the registration application of certain medical supplies in China.

1. Registration requirements for coronavirus reagent test kits

As of 30.03.2020, a total of 23 coronavirus test kits (15 nucleic acid reagent test kits and 8 antibody test kits) had been registered with NMPA emergency approvals. Coronavirus reagent test kits are classified as Class III medical devices, and are required to submit the following materials for the application of NMPA registration:

– Application form

– Proof of qualifications

– General information

– Research information on the major raw materials used

– Research information of the manufacturing techniques and reaction systems

– Performance analysis

– Information to determine positive value or relevant references

– Research information on the stability performance

– Records of production and self-testing

– Clinical evaluation information

– Risk analysis

– Technical requirements

– Testing reports for product registration

– Instructions for use

– Samples of labelling

– Declaration of conformity

2. Regulatory requirements for medical protective equipment

– NMPA guideline for technical review of medical face masks

– NMPA guideline for technical review of single-use surgical gowns

– NMPA guideline for technical review of single-use surgical packs

3. Product standards for medical protective equipment

– GB19082-2009 Technical Requirements for Single-use Protective Clothing for Medical Use

– GB19083-2010 Technical Requirements for Protective Face Masks for Medical Use

– YY/T0969-2013 Single-use Medical Face Mask

– YY0469-2011 Surgical Masks

4. Enhanced market surveillance of medical protective equipment

Medical masks and protective clothing

– China regulatory standards for Class II medical devices

– Manufacturers must obtain the appropriate licenses issued by the provincial MPA before production

Goggles and face shields

– China regulatory standards for Class I medical devices

– Manufacturers must file the records with the municipal MPA before production

QMS / GMP

– Manufacturers must establish a QMS (Quality Management System) for operation procedures to ensure the medical device products manufactured meet technical requirements

– Manufacturers must meet the requirements of GMP (Good Manufacturing Practice)

– Manufacturers must meet the requirements of GMP for sterile medical devices, if applicable

– Manufacturers are responsible to conduct self-inspections regularly and submit report results to the provincial MPA

5. Strengthen post-market surveillance of coronavirus reagent test kits registered with emergency approval

– Provincial MPAs are required to strengthen their post-market supervision on manufacturers

– NMPA Legal Agents must fulfil the responsibility to monitor and report any adverse incidents in a timely manner

On 09.04.2020, the Standardization Administration of the SAMR (State Administration for Market Regulation) announced plans to release 13 foreign language versions of national standards to address the technical requirements of protective face masks, giving support to more than 30 coronavirus affected countries such as Bangladesh, Serbia, Italy, Iran, etc.

By Jacky Li. Contact Cisema to learn more.

Tagged under: COVID-19

What you can read next

Quality Control on Coronary Stents Increased Following China’s Recent Centralized Procurement Program
China Adjusts Import Tariff of Medical Devices
Cisema Participates in VDDI Quarterly Meeting

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...
  • China medical device quality safety responsibility

    China medical device quality and safety responsibility regulations come into force on March 1, 2023

    China medical device quality and safety respons...
  • China drug standards draft measures

    China drug standards draft measures have been published by the NMPA

    China drug standards draft measures have recent...
  • China special equipment safety supervision

    China special equipment safety supervision – draft provisions released

    China special equipment safety supervision regu...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.